Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease
DBS is a proven therapy for managing many symptoms of Parkinson's disease and has been prescribed for a variety of neurological disorders. Hundreds of thousands of DBS implantations around the world have helped patients manage PD, dystonia, essential tremor, OCD, and more. Conventional DBS devices deliver continuous stimulation at fixed settings. While the therapy has been effective for decades, new techniques and technology have allowed for significant improvement to the customization of DBS therapy.
Newronika's AlphaDBS monitors the patient's brain activity and automatically adjusts stimulation levels in response to real-time neurophysiological feedback. This personalized approach optimizes symptom control while reducing side effects and minimizing the need for frequent programming adjustments by neurologists.
"The CE Mark approval of AlphaDBS is a defining moment for Newronika and for the field of deep brain stimulation," said Lorenzo Rossi, CTO and Co-Founder of Newronika. "This certification validates our vision of bringing truly adaptive neuromodulation to patients. We are excited to bring this technology to market and to set a new standard in the treatment of Parkinson's disease."
The CE Mark approval is based on clinical data demonstrating the safety and effectiveness of the AlphaDBS in delivering adaptive deep brain stimulation. Clinical trials for adaptive DBS have shown that patients experience more time without symptoms or side effects compared to conventional DBS, with improved overall quality of life and greater patient preference for the adaptive stimulation mode.
With this regulatory milestone, Newronika is preparing for the commercial launch of AlphaDBS in select European markets in 2025. The company is also advancing its global expansion, including its recently announced Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial in the United States.
About Newronika
Newronika is a spin-off of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, and s transforming deep brain stimulation (DBS) through its adaptive platform that uses real-time patient data to optimize therapy. Headquartered in Milan, Italy, the company is committed to advancing neuromodulation beyond conventional limitations. With ongoing research collaborations, a CE Mark for its technology, and now an Investigational Device Exemption from the FDA, Newronika stands at the forefront of next-generation therapeutic innovation for neurological disorders.
For more information, visit www.newronika.com or follow us on LinkedIn.
Logo - https://mma.prnewswire.com/media/2612569/5150136/Newronika_Logo.jpg
ContactMichael FattoreCFO+39 02 84109381info@newronika.com
View original content:https://www.prnewswire.com/news-releases/newronika-receives-ce-mark-approval-for-alphadbs-advancing-adaptive-deep-brain-stimulation-for-parkinsons-disease-302408062.html
SOURCE Newronika
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
New Peer-Reviewed Study in New England Journal of Medicine Catalyst Finds Twin Health's AI Precision Treatment Significantly Improves Outcomes in Patients with Type 2 Diabetes and Reduces Reliance on Costly Medications, Including GLP-1s
Cleveland Clinic-led study finds Twin Health's precision AI and hyper-personalized care outperforms standard diabetes treatment—reducing A1C, unhealthy weight, and medication use MOUNTAIN VIEW, Calif., Aug. 20, 2025 /PRNewswire/ -- Today, Twin Health announced the publication of results from a Cleveland Clinic-led study in the New England Journal of Medicine Catalyst, evaluating its Twin Precision Treatment for the management of type 2 diabetes. The program features technology-driven interventions that leverage artificial intelligence to deliver personalized insights and lifestyle recommendations aimed at improving glycemic control and metabolic health in adults with type 2 diabetes. The findings, published today, showed that 71% of study participants using the Twin Precision Treatment system met the primary endpoint of achieving an A1C below 6.5% while eliminating most blood sugar-lowering medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and insulin. Type 2 diabetes affects nearly 1 in 10 Americans, and prolonged elevated blood sugar levels increase the risk of serious complications like heart disease, kidney failure, and stroke. Twin Precision Treatment System Uses Artificial Intelligence, Machine Learning and Wearable Sensors for Sustainable Results Developed by Twin Health, the Twin Precision Treatment combines digital twin AI with personalized clinical care, including licensed providers, nurses, and coaches. Using data from wearable sensors, the system continuously tracks real-time health metrics such as blood glucose levels, weight, blood pressure, stress, physical activity, and sleep. Users access these insights through a smartphone app, offering personalized nutrition and exercise guidance, encouraging patients to achieve their goals and sustainable health improvements. The specific app-generated dietary recommendations were based on AI-enabled predictions of each patient's blood glucose responses to specific meals. "The study demonstrates that AI-driven precision medicine is the key to metabolic healing," said Dr. Lisa Shah, chief medical officer and executive vice president of Twin Health. "We're committed to our mission of producing real results for real people. This study is an important milestone on that journey and a glimpse into what's ahead for the future of metabolic care." Kevin M. Pantalone, D.O., Director of Diabetes Initiatives at the Cleveland Clinic and a professor of medicine at the Cleveland Clinic Lerner College of Medicine, served as the primary investigator for this study. For the clinical trial (NCT05181449), researchers aimed to determine whether Twin Health's Twin Precision Treatment system could help individuals with type 2 diabetes, managed in a primary care setting, achieve their blood sugar goals while also eliminating glucose-lowering medications. "In routine clinical practice, type 2 diabetes is often treated with a one-size-fits-all approach where individuals are prescribed medications and told to 'watch their diet and stay active," said Dr. Pantalone. "Our study demonstrated the AI-enabled system of sensors to understand each patient's unique metabolic profile, and AI-enabled human care team coaching facilitated significant improvements in glycemic control, weight loss, and quality of life versus usual care, while allowing marked de-escalation of glucose-lowering medications. Interventions like this system can help patients make informed, lasting lifestyle changes to control their blood sugar and sustain weight loss." Dr. Pantalone collaborated with a team of 13 primary care physicians to recruit 150 patients from the Cleveland Clinic Twinsburg Family Health Center located in Twinsburg, Ohio. Of these, 100 were assigned to the Twin Precision Treatment group and 50 to the standard of care group. On average, patients were 58.5 years old, had been living with type 2 diabetes for about nine years, and presented with a mean body mass index (BMI) of 35.1 and an average A1C level of 7.2%. The primary endpoint was to see how many participants reached an A1C below 6.5% after 12 months without needing any glucose-lowering medications except for metformin, a common low-cost diabetes medication. After one year, a majority of study participants in the Twin intervention group achieved an A1C below 6.5% After one year, 71% of participants enrolled in the intervention group lowered their A1C levels below the 6.5% threshold, while taking only metformin. By comparison, only 2.4% of participants receiving standard care achieved the same result. Participants in the Twin intervention group also lost more weight (8.6% vs 4.6% of body weight) while significantly reducing their reliance on medications: GLP-1 Receptor Agonist medication use decreased from 41% to 6% among participants SGLT-2 Inhibitor use decreased from 27% to 1% of participants Dipeptidyl peptidase-4 (DPP-4) inhibitor use decreased from 33% to 3% in participants Insulin use decreased from 24% to 13% among participants The quality of life scores and treatment satisfaction were notably better for those using the Twin Precision Treatment, highlighting its potential as a highly effective and sustainable option for diabetes management. Real-World Reduction in GLP-1 UseIn the Cleveland Clinic-led study, 85% of participants in the Twin Health program eliminated GLP-1s, demonstrating that many individuals can sustain clinical goals without long-term dependence. Translating Clinical Success into Cost SavingsTwin Health is proven effective for diabetes, weight loss and metabolic health comorbidities, including hypertension. Twin Health's real-world results echo the RCT findings, delivering over $8,000 in average first-year savings per member. These savings result from reducing reliance on high-cost medications, such as GLP-1s, and avoiding unnecessary care utilization, making Twin a scalable and cost-effective solution for employers and health plans seeking to address the growing burden of metabolic disease. About Twin HealthTwin Health's AI digital twin technology creates a real-time model of each individual's unique metabolism using data from smart devices, lab results, and meal logs. This model provides personalized guidance on nutrition, activity, sleep, and more, supported by a compassionate clinical team. Twin's AI digital twin and human care work in synergy, providing a continuous new standard of care for metabolic health. For employers and health plans, Twin delivers $8.0K+ in annualized savings per member by safely reducing reliance on high-cost medications and lowering avoidable medical utilization. Twin's clinical results for diabetes, weight loss and metabolic health co-morbidities, including hypertension, are peer-reviewed and published in top journals, including the New England Journal of Medicine Catalyst and those of the American Heart Association, American Diabetes Association, and American College of Cardiology. Learn more at Press ContactAlex McKechnieAOX3 for Twin View original content to download multimedia: SOURCE Twin Health Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
FDA warning: Don't eat these potentially radioactive shrimp sold at Walmart
You might want to think twice about buying this brand of shrimp next time you're shopping at Walmart. The U.S. Food and Drug Administration issued a warning to consumers about eating, selling or serving select brands of Great Value frozen raw shrimp due to contamination with a radioactive isotope. U.S. Customs and Border Protection alerted the FDA about the radioactive isotope, Cesium-137, after it was found in shipping containers at four U.S. seaports, according to the FDA. Here's what you need to know about the products that are affected and whether a recall will be imminent. What contaminated shrimp is the FDA warning consumers about? The Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp in 2-pound bags distributed by Indonesia's BMS Foods tested positive for the contamination. The FDA is recommending a recall on certain BMS shrimp products even if they did not test positive. While a recall hasn't been conducted yet, the FDA is working with distributors and retailers 'to recommend' a recall. The following products are affected: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027 The products were sold in Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. What should people do if they have the contaminated raw shrimp? The FDA is advising people who might have raw, frozen shrimp in their freezers from Walmart that matches the descriptions to not cook or consume them. Instead, the agency is asking customers, distributors and retailers to throw the shrimp away. The FDA also says, 'If you suspect you have been exposed to elevated levels of cesium, talk to your healthcare provider.' Consuming food or water contaminated with Cs-137 in low doses over an extended period of time can create an elevated risk of cancer due to a breakdown in DNA in the body's living cells, according to the FDA. Our journalism needs your support. Please subscribe today to Katherine Rodriguez can be reached at krodriguez@ Have a tip? Tell us at Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
AskNewt Unveils Version 3.0, Bringing Trusted, Accurate, Smarter, Faster, and More Personalized AI Insights to Finance and Everyday Life
The latest release introduces real-time, context-aware analysis, secure portfolio tools, and persistent memory — delivering sharper answers and a safer, more personalized user experience. NEW YORK, Aug. 20, 2025 /PRNewswire/ -- AskNewt, a leading provider of AI-powered financial and personal insights, today announced the upcoming release of AskNewt Version 3.0, the company's most advanced platform update to date. Built on direct feedback from its growing user community, AskNewt 3.0 introduces powerful new features designed to enhance accuracy, speed, and personalization across financial research, decision-making, and everyday use. "AskNewt 3.0 represents a major step forward in how individuals and professionals can leverage AI for timely, accurate, and actionable insights," Chief AI Officer Abbas Shah said, adding that "Our goal is to deliver a smarter and safer AI assistant that not only answers questions, but also anticipates user needs, learns preferences, and supports critical decision-making in real time." Key Features of AskNewt 3.0: Sharper Answers, Faster – Advanced parsing of financial and general queries powered by the latest large language models. Real-Time, Context-Aware Insights – Information and analysis that reflect current events and market conditions. Personalized Experience – Persistent memory that adapts to each user's profile, interests, and history. Smarter Financial Tools – Secure portfolio uploads with real-time performance tracking and instant stock analysis. Everyday Intelligence – Expanded support for trip planning, restaurant booking, shopping deals, and more. Streamlined Interface – A cleaner, more focused design for seamless user experience. Continuous Self-Improvement – A system that learns and improves with each engagement. Private by Design – Strict commitment to data privacy, with no sharing of user information with third parties. About AskNewtNew York-based AskNewt, LLC has developed AskNewt, an AI Agentic search engine built for sharper, faster answers—especially for financial and complex queries. It delivers real-time, context-aware insights with verified accuracy, a streamlined interface, and personalized results that improve over time. Private by design and free to use, AskNewt aims to reach 15–20 million users in two years, following a proven B2C growth and monetization model. Download the mobile apps here for AskNewt: Apple Store link Google Play link View original content to download multimedia: SOURCE AskNewt, LLC
